Clofutriben

Clofutriben is Sparrow Pharmaceuticals' selective 11β-HSD1 inhibitor (originally Astellas' ASP3662, later SPI-62) being tested across three cortisol-driven indications. The primary efficacy de-risking event for the molecule is the RESCUE Phase 2 trial in endogenous Cushing's syndrome (completed October 2024), in which more than 60% of clofutriben-treated patients normalized 24-hour urinary free cortisol versus 0% on placebo, and all eligible completers entered the open-label extension [8][9]. That readout earned FDA Orphan Drug Designation for endogenous Cushing's syndrome later the same month [8]. A separate Phase 2 readout in polymyalgia rheumatica, published in Annals of the Rheumatic Diseases in early 2026, showed patients could taper prednisolone with fewer steroid side effects when clofutriben was added [2]. The third and largest program is CAPTAIN-T2D, a 1,500-patient Phase 2 enrolling Type 2 Diabetes patients with biochemical hypercortisolism, with the first patient dosed January 6, 2026 [3]. The thesis: a meaningful slice of treatment-resistant T2D is driven by tissue-level cortisol overload, and four prior 11β-HSD1 programs failed not because the mechanism is broken but because they enrolled all comers when the effect size only clears the commercial bar in cortisol-enriched patients.

Novel compound. Originally ASP3662 from Astellas, in-licensed by Sparrow Pharmaceuticals and developed under the SPI-62 designation across multiple cortisol-driven indications [8]. **Completed Phase 2 (RESCUE) in endogenous Cushing's syndrome** - randomized, placebo-controlled, 12-week treatment with 12-week crossover; primary outcome announced October 2024 showed >60% UFC normalization on clofutriben vs 0% on placebo, morning cortisol maintained safely above 10 µg/dL, and all eligible completers enrolled in the open-label extension [8][9]. **FDA Orphan Drug Designation granted October 28, 2024 for endogenous Cushing's syndrome** [8] - confers seven years of post-approval market exclusivity, tax credits for qualifying trials, and PDUFA fee waiver. **Phase 2 in polymyalgia rheumatica** - sequential-cohort data published in Annals of the Rheumatic Diseases (2026) demonstrating reduced glucocorticoid side effects when clofutriben was added to tapering prednisolone [2]. **Lead T2D study, CAPTAIN-T2D (NCT07296484)** - 1,500-patient Phase 2, first patient enrolled January 6, 2026, currently recruiting [3]. Two supporting Phase 1 trials: pharmacokinetics in impaired renal function (NCT07227922, recruiting) and a midazolam/prednisolone DDI study (NCT07226635, completed); the DDI study is strategically important because clofutriben's PMR value depends on co-administration with prednisolone without altering its exposure [4][5]. No public disclosure of dose used in CAPTAIN-T2D or whether it mirrors the RESCUE Cushing's dose. T2D readout timing not disclosed; with a 1,500-patient two-part trial in early recruiting, expect no sooner than Q4 2027.

Cortisol is the body's main stress hormone. It raises blood sugar, breaks down muscle, and drives fat storage in the belly and liver. The kidney, via a related enzyme called 11β-HSD2, actively inactivates cortisol to cortisone, keeping circulating levels in check. But individual tissues, especially fat and liver, contain a different enzyme called 11β-HSD1 that runs the reaction in reverse and turns cortisone back into cortisol locally. So even when blood cortisol looks normal, fat and liver can be marinating in extra cortisol they regenerated themselves. That's the rationale: blocking 11β-HSD1 lowers cortisol exactly where it's doing metabolic damage without disturbing the brain's cortisol thermostat. The mechanism is well-validated genetically (people with conditions causing 11β-HSD1 overactivity show metabolic syndrome features) and in mouse models that overexpress the enzyme in adipose tissue, which produces Cushing's-like fat distribution. The clinical history is where context matters. Four prior 11β-HSD1 programs reached Phase 2 in unselected T2D in the 2010s: AstraZeneca's AZD4017, Pfizer's PF-915275, Incyte's INCB13739, and Merck's MK-0916. INCB13739 actually showed a statistically significant ~0.6% HbA1c reduction (a measure of average blood sugar over the past three months; normal is below 5.7%, T2D is typically 7-9%) on top of metformin, concentrated in obese patients [6]. MK-0916 produced a smaller but real ~0.3% A1C reduction at the high dose [7]. These were not mechanism failures - they were modest signals that didn't justify Phase 3 investment as DPP-4 inhibitors and SGLT2 inhibitors rapidly improved the competitive bar. Sparrow's bet has two legs: (1) the absolute effect size goes up substantially when you select patients with documented biochemical hypercortisolism, and (2) clofutriben's pharmacology is better - the 2025 An et al. paper in Clinical and Translational Science showed pseudo-irreversible binding and no tachyphylaxis (loss of drug effect over repeated dosing) in human adipose tissue, a real problem with some earlier reversible inhibitors [1].

CAPTAIN-T2D (NCT07296484) is a two-part Phase 2 in T2D patients with elevated cortisol risk factors. Part 1 is a screening study that evaluates whether patients have biochemical hypercortisolism, defined by a composite of morning cortisol above 1.8 µg/dL plus dexamethasone ≥140 ng/dL after an overnight 1mg dexamethasone suppression test [3]. Only patients who fail to suppress cortisol despite the dex challenge advance into Part 2, the placebo-controlled drug-treatment phase. Enrollment target is 1,500 across both parts; first patient enrolled January 6, 2026; sponsor Sparrow Pharmaceuticals. The screening arm itself is informative because it generates real-world prevalence data on how much T2D in cortisol-risk patients is actually driven by hypercortisolism, a number that's been debated for a decade. The design risk: the 1mg overnight dex test has known false-positive rates in diabetic patients because cortisol-binding globulin and dexamethasone metabolism both shift with obesity and insulin resistance. If you over-enrich based on a noisy biomarker, treatment effect dilutes. The strength: this is exactly the patient stratification the prior generation of 11β-HSD1 trials skipped, and it is the most defensible reason this program could succeed where Pfizer and AstraZeneca declined to push to Phase 3. The Part 2 efficacy endpoint (presumably HbA1c-based) and the dose level aren't yet detailed in the public registry - both are gaps to watch as the protocol matures. The completed RESCUE trial in Cushing's syndrome used a 12-week placebo-controlled phase with 12-week crossover, an OLE for completers, and produced a clean separation on UFC normalization (>60% vs 0%) [8][9] - that is the cleanest existing efficacy benchmark the T2D readout will be measured against.

About 1 in 10 drugs at this stage ultimately get approved, and the model estimates this one has a 10% chance. It starts from the historical approval rate for Phase 2 drugs in this area - around 35% - then adjusts based on ten specific facts about the trial and sponsor. On the positive side, enrollment is larger than typical for this phase. Working against it: the blinding setup is heavier than usual, the sponsor has a thin or weak approval track record, and earlier-phase results were limited or weak.

Class commercial history is the dominant T2D-program risk, but it needs framing. The four prior 11β-HSD1 Phase 2 programs (AZD4017, PF-915275, INCB13739, MK-0916) did not show a broken mechanism - INCB13739 produced a statistically significant ~0.6% HbA1c reduction in obese patients on metformin [6], and MK-0916 a more modest ~0.3% reduction [7]. They were shelved because those effect sizes did not justify Phase 3 against a competitive landscape that was rapidly improving (DPP-4s, SGLT2s, then GLP-1s). Sparrow's enrichment thesis is a bet that effect size goes up substantially in patients with documented biochemical hypercortisolism. That bet is reasonable but unproven, and the burden of proof is on them. Safety risk is moderate but not severe: tissue-selective 11β-HSD1 inhibition is mechanistically mild compared with systemic cortisol blockade, the RESCUE readout reported morning cortisol maintained safely above 10 µg/dL with no adrenal insufficiency signal, and all eligible completers entered the OLE - a meaningful tolerability and durable-efficacy signal [9]. Compensatory ACTH and cortisol rise from the pituitary has been documented across the class, and adrenal hyperplasia has appeared in rodent toxicology at high doses, so HPA-axis surveillance remains warranted. Commercial risk in T2D is the underappreciated one. T2D is the most price-pressured market in pharma right now, dominated by GLP-1 receptor agonists (semaglutide, tirzepatide) that drop HbA1c 1.5-2.0% AND drive 15-20% weight loss. A 11β-HSD1 inhibitor would need to beat that benchmark in a defined niche (steroid-induced diabetes, Cushing's-spectrum T2D) or position as adjunct, and payer coverage in either case will be tight. Execution risk: Sparrow is single-asset, recently public, and a 1,500-patient trial burns cash quickly. Financing risk through readout is non-trivial and should factor into any equity thesis. The orphan-designated Cushing's pathway substantially de-risks the regulatory and reimbursement profile of at least one indication.

Worth watching, and the strategic picture is materially better than it looked at first read. The RESCUE Phase 2 readout in endogenous Cushing's syndrome (>60% UFC normalization vs 0% placebo) plus FDA Orphan Drug Designation makes Cushing's syndrome a near-term commercial pathway with seven years of post-approval exclusivity, a small and well-defined patient population, and a clean payer story - Cushing's syndrome treatment is currently dominated by older agents with adverse profiles, so a tolerable oral with that level of UFC response has obvious commercial uptake [8][9]. The PMR Phase 2 in Annals of the Rheumatic Diseases is a second cleaner commercial story than chasing GLP-1s in T2D: endocrinologists and rheumatologists understand cortisol pathway pharmacology, payers understand iatrogenic Cushing's from chronic steroids, and the steroid-sparing bar is lower than going head-to-head with semaglutide [2]. The specific T2D signal to watch in CAPTAIN-T2D: whether the dex-suppression-enriched population shows a 0.5%+ HbA1c separation from placebo, and whether weight changes are flat or modest loss (anything resembling weight gain kills commercial uptake in this market) [3]. Check back when CAPTAIN-T2D completes enrollment (likely late 2026 to early 2027) and again at first interim. The bigger picture: Sparrow is running clofutriben as a single-molecule, multi-indication play across Cushing's syndrome, PMR, and T2D [8]. With Cushing's already orphan-designated and de-risked, PMR holding up, and T2D as the largest commercial upside, Sparrow is now the most credible cortisol-pathway company in biotech - a strategic position any large pharma in endocrinology or rheumatology should be tracking.